FASN and metabolic disease: TVB-2640 (denifanstat), which inhibits FASN β-ketoacyl reductase activity, is the most clinically advanced FASN inhibitor (94), and it is currently in clinical trials for the treatment of metabolic disorders, several cancers, and dermatology indications.